Europe Nuclear Medicine Market Size & Outlook, 2025-2030

The nuclear medicine market in Europe is expected to reach a projected revenue of US$ 7,111.6 million by 2030. A compound annual growth rate of 11.9% is expected of Europe nuclear medicine market from 2025 to 2030.
Revenue, 2024 (US$M)
$3,397.4
Forecast, 2030 (US$M)
$7,111.6
CAGR, 2025 - 2030
11.9%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe nuclear medicine market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe nuclear medicine market highlights

  • The Europe nuclear medicine market generated a revenue of USD 5,227.1 million in 2024.
  • The market is expected to grow at a CAGR of 7.9% from 2025 to 2030.
  • In terms of segment, diagnostics was the largest revenue generating product in 2024.
  • Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, Denmark is expected to register the highest CAGR from 2025 to 2030.

Europe data book summary

Market revenue in 2024USD 5,227.1 million
Market revenue in 2030USD 8,243.5 million
Growth rate7.9% (CAGR from 2025 to 2030)
Largest segmentDiagnostics
Fastest growing segmentDiagnostics
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationDiagnostics, Therapeutics
Key market players worldwideGE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc

Other key industry trends

  • In terms of revenue, Europe region accounted for 23.7% of the global nuclear medicine market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 7,134.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Nuclear Medicine Market Companies

Name Profile # Employees HQ Website
Abliva AB View profile 6 Scheeletorget 1, Medicon Village, Lund, Sweden, 223 81 https://www.abliva.com
Iren SpA View profile 10000 Via Nubi di Magellano, 30, Reggio Emilia, Italy, 42123 https://www.gruppoiren.it
Jubilant Pharmova View profile 10001+ Noida, Uttar Pradesh, India, Asia https://www.jubilantpharmova.com
Lantheus Holdings Inc View profile 834 201 Burlington Road, South Building, Bedford, MA, United States, 01730 https://www.lantheus.com
Bracco View profile 1001-5000 Milan, Lombardia, Italy, Europe https://www.bracco.com
Nordion View profile 251-500 Kanata, Ontario, Canada, North America http://nordion.com
Eckert & Ziegler Bebig SA View profile 501-1000 Seneffe, Hainaut, Belgium, Europe http://www.ezag.com/home/
Mallinckrodt PLC Ordinary Shares - New View profile 2700 College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 https://www.mallinckrodt.com
Cardinal Health Inc View profile 48000 7000 Cardinal Place, Dublin, OH, United States, 43017 https://www.cardinalhealth.com
GE HealthCare Technologies Inc Common Stock View profile 51000 500 West Monroe Street, Chicago, IL, United States, 60661 https://www.gehealthcare.com

Europe nuclear medicine market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.


Diagnostics was the largest segment with a revenue share of 76.56% in 2024. Horizon Databook has segmented the Europe nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.


Europe holds the second largest share of the market owing to factors such as rising prevalence of cancer and growing geriatric population, which is highly susceptible to cardiovascular and neurological disorders.

In addition, introduction of new isotopes for diagnostic (Ga-67/Ge-68) and therapeutic (Sr-90/Y-90 or W188/Re-188) purposes is expected to accelerate market growth in Europe during the forecast period. Radioisotopes are widely used in Europe for the diagnosis and treatment of cancer, cardiovascular diseases, & others.

Nuclear medicine has shown major potential in the treatment of cancer and cardiovascular diseases. According to WHO, in Europe, approximately 3.7 million new cancer cases reported each year, making it the second leading cause of death and morbidity.

Reasons to subscribe to Europe nuclear medicine market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe nuclear medicine market databook

  • Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe nuclear medicine market , including forecasts for subscribers. This continent databook contains high-level insights into Europe nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe nuclear medicine market size, by country, 2018-2030 (US$M)

Europe Nuclear Medicine Market Outlook Share, 2024 & 2030 (US$M)

Europe nuclear medicine market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online